A practical reference on peptide analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-21 and is reviewed periodically as new material appears.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Oxford's Joint European Torus nuclear fusion laboratory conducts its final experiments after 40 years in operation. 15 October First Minister of Scotland Humza Yousaf signals a change in his party's Scottish independence strategy, now saying that an SNP win in a majority of Scotland's Westminster seats would give the party a mandate to begin independence negotiations with the Westminster Government. One person is killed and another is wounded in a stabbing attack in Hartlepool. The attack is being investigated by Counter Terrorism Policing. A suspect has been detained. 16–22 October – Storm Babet hits the UK, bringing disruption to much of the country. Red weather warnings are issued by the Met Office, as three deaths are reported, and power shortages affect tens of thousands in Scotland. The crew of a Danish fishing trawler are rescued by the RNLI in the North Sea. 16 October Prime Minister Rishi Sunak confirms that six British citizens were killed during the Hamas attacks on Israel, while a further ten are missing. Two British teenage sisters, Noya and Yahel Sharabi, are among those missing, and believed to have been kidnapped, following the 7 October attacks on Israel. Their mother, Lianne, also a British citizen, was killed in the Be'eri massacre. The following day the girls' family tells the BBC the Yahel was also murdered. On 22 October the family release a statement to say Noya was also murdered. Guardian cartoonist Steve Bell is sacked following a row over a drawing he created of Israeli prime minister Benjamin Netanyahu that was deemed to be antisemitic.
=== Human genes === Na+/K+ transporting: ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3, ATP1B4 Ca2+ transporting: ATP2A1, ATP2A2, ATP2A3, ATP2B1, ATP2B2, ATP2B3, ATP2B4, ATP2C1, ATP2C2 H+/K+ exchanging: ATP4A H+ transporting, mitochondrial: ATP5F1A, ATP5F1B, ATP5F1C, ATP5C2, ATP5F1D, ATP5F1E, ATP5F1, ATP5MC1, ATP5MC2, ATP5MC3, ATP5PD, ATP5ME, ATP5PF, ATP5MF, ATP5MG, ATP5L2, ATP5PO, ATP5S, MT-ATP6, MT-ATP8 H+ transporting, lysosomal: ATP6AP1, ATP6AP2, ATP6V1A, ATP6V1B1, ATP6V1B2, ATP6V1C1, ATP6V1C2, ATP6V1D, ATP6V1E1, ATP6V1E2, ATP6V1F, ATP6V1G1, ATP6V1G2, ATP6V1G3, ATP6V1H, ATP6V0A1, ATP6V0A2, ATP6V0A4, ATP6V0B, ATP6V0C, ATP6V0D1, ATP6V0D2, ATP6V0E Cu2+ transporting: ATP7A, ATP7B Class I, type 8: ATP8A1, ATP8B1, ATP8B2, ATP8B3, ATP8B4 Class II, type 9: ATP9A, ATP9B Class V, type 10: ATP10A, ATP10B, ATP10D Class VI, type 11: ATP11A, ATP11B, ATP11C H+/K+ transporting, nongastric: ATP12A type 13: ATP13A1, ATP13A2, ATP13A3, ATP13A4, ATP13A5
=== tib-tie === tibalosin (INN) tibeglisene (INN) tibenelast (INN) tibenzate (INN) tibezonium iodide (INN) tibolone (INN) tibric acid (INN) tibrofan (INN) ticabesone (INN) ticagrelor (USAN) ticarbodine (INN) ticarcillin (INN) ticarcillin/clavulanic acid TICE BCG (Organon Teknika Corp) ticlatone (INN) Ticlid ticlopidine (INN) ticolubant (INN) tideglusib (INN) tidembersat (INN) tidiacic (INN) tiemonium iodide (INN) tienilic acid (INN) tienocarbine (INN) tienopramine (INN) tienoxolol (INN)
Nandrolone was probably among the first anabolic steroids to be used as a doping agent in sports in the 1960s. It has been banned at the Olympics since 1974. There are many known cases of doping in sports with nandrolone esters by professional athletes.
== FSH and LH preparations == hMG (human Menopausal Gonadotrophins), FSH and LH prepared from human urine collected from postmenopausal women. First extracted in 1953. Injected intra-muscularily (IM) or subcutaneously (SC). Generic
Sources: en.wikipedia.org
== Rhabdomyolysis == Exertional rhabdomyolysis is an extreme and potentially deadly form of overtraining that leads to a breakdown of skeletal muscle which makes its way into the blood. Many molecules such as potassium, creatine kinase, phosphate, and myoglobin are released into circulation. Myoglobin is the protein that causes the lethal reaction in the body. Early detection of the syndrome is essential in full recovery. A serious late complication of rhabdomyolysis which occurs in 15% of the population is acute kidney injury, and in some cases it can lead to death.
The argument that Belgians would believe it was butter if it was not cube shaped was disproportionate: it would "considerably exceed the requirements of the object in view" and labelling would protect consumers "just as effectively". In a 2003 case, Commission v Italy Italian law required that cocoa products that included other vegetable fats could not be labelled as "chocolate". It had to be "chocolate substitute". All Italian chocolate was made from cocoa butter alone, but British, Danish and Irish manufacturers used other vegetable fats. They claimed the law infringed article 34. The Court of Justice held that a low content of vegetable fat did not justify a "chocolate substitute" label. This was derogatory in the consumers' eyes. A 'neutral and objective statement' was enough to protect consumers. If member states place considerable obstacles on the use of a product, this can also infringe article 34. So, in a 2009 case, Commission v Italy, the Court of Justice held that an Italian law prohibiting motorcycles or mopeds pulling trailers infringed article 34. Again, the law applied neutrally to everyone, but disproportionately affected importers, because Italian companies did not make trailers. This was not a product requirement, but the Court reasoned that the prohibition would deter people from buying it: it would have "a considerable influence on the behaviour of consumers" that "affects the access of that product to the market". It would require justification under article 36, or as a mandatory requirement.
==== Phosphate reduction ==== A key goal in the management of chronic kidney disease in cats is to reduce dietary phosphate intake early in the course of the disease. As a rule of thumb, the phosphate content can be reduced to 170 mg/MJ UE (Megajoule metabolizable energy, see also Physiological calorific value), i.e. to two thirds of the maintenance requirement. Commercially available cat food usually contains twice the maintenance requirement and should therefore not be mixed with the diet food. If the phosphate levels in the plasma remain elevated despite the renal diet, absorption in the intestine can be reduced by using calcium salts and phosphate binders such as aluminum hydroxide, aluminum carbonate or lanthanum carbonate. Calcium carbonate can compensate for calcium deficiency in the early stages, but can lead to hypercalcemia in advanced stages. The use of phosphate binders should be monitored by blood tests and their dose adjusted on the basis of phosphate levels. Several studies have shown that a reduction of phosphate in the diet is sufficient to slow down the progression of the disease. If the general condition continues to deteriorate during phosphate reduction, a phosphate deficiency should also be considered. This manifests itself in a similar way to chronic kidney disease: shaggy coat, loss of appetite, weakness, exhaustion and anaemia. Calcitriol can also be used to treat secondary hyperparathyroidism, but only if parathyroid hormone and calcium levels are monitored.
=== Non-enzymatic additions in vitro === biotinylation: covalent attachment of a biotin moiety using a biotinylation reagent, typically for the purpose of labeling a protein. carbamylation: the addition of isocyanic acid to a protein's N-terminus or the side-chain of Lys or Cys residues, typically resulting from exposure to urea solutions. oxidation: addition of one or more oxygen atoms to a susceptible side-chain, principally of Met, Trp, His or Cys residues. Formation of disulfide bonds between Cys residues. pegylation: covalent attachment of polyethylene glycol (PEG) using a pegylation reagent, typically to the N-terminus or the side-chains of Lys residues. Pegylation is used to improve the efficacy of protein pharmaceuticals.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.